Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Sanofi–aventis announced that the investigational anti–Xa intravenous anticoagulant otamixaban reduced by 27 to 42 percent the odds of the composite primary endpoint of death, myocardial infarction, urgent revascularization or rescue GPIIb/IIIa use in 4 out of the 5 otamixaban tested doses, versus standard UFH/eptifibatide combination in ACS patients suitable for invasive strategy. The results of the SEPIA–ACS1/ TIMI–42 were presented at the plenary session of the Annual European Society of Cardiology congress in Barcelona and simultaneously published online in The Lancet.

Today in Cardiac/Hypertension...keeping you current

The role of pulmonary veins in atrial fibrillation
Pharmacology & Therapeutics, 11/24/09

Telmisartan prevents cardiovascular events in a broad group of at-risk patients
Expert Opinion in Pharmacotherapy, 11/23/09

Chronic nitrate therapy is associated with different presentation and evolution of acute coronary syndromes: insights from 52 693 patients in the Global Registry of Acute Coronary Events
European Heart Journal, 11/23/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address